Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $48.45 Consensus PT from Brokerages

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their […]

Leave a Reply

Your email address will not be published.

Previous post Nordstrom (NYSE:JWN) Price Target Lowered to $17.00 at Piper Sandler
Next post Analysts Set Cisco Systems, Inc. (NASDAQ:CSCO) Target Price at $58.38